ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pediatric

seanbear/shutterstock.com

Volunteers Wanted to Join the ACR’s Committees, Board of Directors, Research Foundation

Sharad Lakhanpal, MBBS, MD  |  April 19, 2017

In 1974, President Nixon established a week in April to recognize the importance of volunteering. National Volunteer Week is scheduled for April 23–29 this year. At the College, we like to acknowledge and thank our volunteers year round. The mission of the College cannot be achieved without the time, effort, talent and dedication of our…

Filed under:Legislation & AdvocacyPresident's PerspectiveResearch Rheum Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)Board of directorsLeadershipmicrovolunteeringrheumatologistRheumatology Research FoundationVolunteer

Quality Measures Used to Assess Care, Improve Outcomes in Children, Adults with Rheumatic Diseases

Mary Beth Nierengarten  |  March 20, 2017

WASHINGTON, D.C.—In a session during the 2016 ACR/ARHP Annual Meeting, aptly called Quality Measures and Quality of Care I, a panel of experts presented information on a number of programs underway in rheumatology using quality measures to both assess and improve patient outcomes. Leading off were two presentations on programs using quality measures to improve…

Filed under:ConditionsMeeting ReportsPediatric ConditionsQuality Assurance/Improvement Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)patient carePediatricPractice ManagementQualityRheumatic Diseaserheumatologistrheumatology

Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors

Thomas R. Collins  |  March 20, 2017

WASHINGTON, D.C.—Juvenile idiopathic arthritis (JIA) patients taking TNF inhibitors don’t develop new cancers at a higher rate than JIA patients who don’t take TNF inhibitors, according to the largest study so far conducted to study the possible link. The findings were reported at the 2016 ACR/ARHP Annual Meeting in an abstract session that also included…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)CancerinhibitorJuvenile idiopathic arthritisPediatricsrateResearchrheumatologyriskTNFTreatment

CHARAN RATTANASUPPHASIRI/shutterstock.com

Funding Sources for Scientific Discovery, Medical Research

Simon M. Helfgott, MD  |  March 20, 2017

The Phone Call A phone call in the middle of the night can rattle one’s nerves. The rush of adrenaline sets the heart pounding as our ears brace for what we are about to hear next. A distress call from an elderly parent or a child away at college? Is everyone safe? Or may this…

Filed under:OpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:discoveryfinancialFundinginvestmentmedicalNational Institutes of HealthPhilanthropyResearchrheumatologysupport

ACR Joins Opposition to Proposed Healthcare Replacement Bill as Written

Mary Beth Nierengarten  |  March 16, 2017

The ACR is joining a chorus of voices asking Congress to reconsider several key provisions in the proposed American Health Care Act (AHCA) that it feels could have a detrimental effect on patients. Characterized as a replacement to the Affordable Care Act (ACA), the AHCA eliminates a number of provisions found in the ACA, although…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Access to careAccess to medicationAffordable Care Act (ACA)American Association of Retired PersonsAmerican Health Care Act (AHCA)American Medical Association (AMA)Capping Medicaidhealthcare provisionsPrevention and Public Health Fund

Prescription-Drug Monitoring Cuts Doctor-Shopping for Painkillers

Ronnie Cohen  |  February 20, 2017

(Reuters Health)—State programs that require physicians to check drug registries before writing prescriptions appeared to slash the odds of doctor-shopping for opioid pain relievers, a new study found. “Our study shows that prescription-drug monitoring programs are a promising component of a multifaceted strategy to address the opioid epidemic,” Ryan Mutter, one of the study authors,…

Filed under:AnalgesicsDrug Updates Tagged with:DrugsOpioid abuseOpioidsprescription-drug monitoring

Rheumatology Practices Need Sharp Focus on Patient Care Safety, Quality

Carina Stanton  |  February 16, 2017

“It is not necessary to change. Survival is not mandatory.” —W. Edwards Deming For practices to survive, change is a requirement—not an option—in the rapidly evolving practice of rheumatology care. Pharmaceutical therapies are advancing quickly, opening the door for game-changing therapies in the treatment of chronic autoimmune disorders. With these advances comes a need for…

Filed under:Practice Support Tagged with:chronic autoimmune disorderpatient carePractice ManagementQualityrheumatologistrheumatologySafetytherapy

Anti-Interleukin-6 Therapy for Erdheim-Chester Disease Warrants Study

Stefanie D. Wade, MD, Michael A. Seidman, MD, Edward C. Jones, MD, Arnold Radu, MD, Ryan Paterson, MD, Vikram Deshpande, MD, John H. Stone, MD, & Mollie N. Carruthers, MD  |  February 16, 2017

Erdheim-Chester disease (ECD) is a rare, non-Langerhan’s cell histiocytosis characterized by tissue infiltration of CD68-positive and CD1a-negative foamy histiocytes.1 ECD was discovered as a lipid granulomatosis in 1930 by Jakob Erdheim and his pupil, William Chester, and approximately 500 cases have been described to date.1 ECD has a heterogeneous course and prognosis ranging from an…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:anti-interleukincase reportClinicalDiagnosisDiseaseErdheim-ChesterinflammatoryinterferonPathogenesistherapyTreatment

The ACR’s 2015 Workforce Study Reveals Gap Between Rheumatologist Supply, Patient Demand

Susan Bernstein  |  February 15, 2017

WASHINGTON, D.C.—In the next 15 years, it will be increasingly difficult to provide adequate care for rising numbers of patients with rheumatic diseases due to a severe shortage of trained rheumatology healthcare providers, according to the ACR’s 2015 Workforce Study of Rheumatology Specialists in the United States. The full study is available online, and panelists…

Filed under:ConditionsMeeting ReportsPediatric ConditionsWorkforce Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)patient carePediatricphysician supplyQualityRheumatic Diseaserheumatologistrheumatologyshortage

Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2017

GCA Relapse Possible When Discontinuing Tocilizumab In a Phase 2 randomized, controlled trial, tocilizumab, an anti-IL-6 biologic agent, was shown to induce and maintain remission for up to 52 weeks in patients with giant cell arteritis (GCA).1 During this trial, patients with GCA were randomized in a 2:1 ratio to receive 8 mg/kg bodyweight tocilizumab…

Filed under:Drug UpdatesResearch Rheum Tagged with:ApprovalsdrugetanerceptFDAGiant Cell Arteritisoutcomepatient careQualityrelapseResearchrheumatologyrituximabSafetytrial

  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 112
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences